Recently, autoantibodies against nodal and paranodal proteins, such as neurofascin186 (NF186), 4 neurofascin155 (NF155), contactin-1 (CNTN1), contactin-associated protein 1 (CASPR1) and 5 gliomedin, have been discovered in not only chronic demyelinating conditions, such as multiple 6 sclerosis (MS) and chronic inflammatory demyelinating polyradiculoneuropathy, but also in acute 7 demyelinating conditions, such as Guillain-Barré syndrome. Only a minority of these patients 8 harbor anti-nodal/paranodal protein antibodies; however, these autoantibodies, especially IgG4 9 subclass autoantibodies to paranodal proteins, are associated with unique features and these 10 conditions are collectively termed nodopathy or paranodopathy. Establishing a concept of 11 IgG4-related nodopathy/paranodopathy contributes to diagnosis and treatment strategy because 12
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or a small series of studies of such cases exist in the literature, in 2012 we conducted the first 1 nationwide survey in Japan to uncover the demographic features of CCPD (Ogata et al., 2016) . 2 3
The nationwide survey results of CCPD 4
Definition: We defined CCPD as fulfilling the following criteria (Ogata et al., 2016) : 5 1. CNS involvement criterion: T2 high-signal intensity lesions in the brain, optic nerves, or spinal 6 cord upon MRI, or abnormalities on visual-evoked potentials (VEPs). 7 2. PNS involvement criterion: conduction delay, conduction block, temporal dispersion or F-wave 8 abnormalities, suggesting peripheral demyelinating neuropathy according to nerve conduction 9
studies (NCS). 10
Demographic features: CCPD is a rare condition; likely less than 0.52% of MS and 2.8% of 11 CIDP patients in Japan, based on the nationwide survey. The mean age at onset was 32 years 12 (range; 8-59 years). The male to female ratio was 1:2.6. The mode of onset was acute in 19.4%, 13 subacute in 45.2%, and chronic in 35.5%. Clinical courses were monophasic in 26.3%, relapsing 14 remitting in 52.6%, and chronic progressive in 21.1%. 15
Neurological manifestations: Onset with CNS symptoms, such as visual disturbance, hemiplegia, 16 and hemibody sensory disturbance, was observed in about 40%, onset with PNS manifestations, 17 such as weakness and sensory disturbance of the four extremities, in around 40%, and onset with 18 both CNS and PNS manifestations in about 20%. The most common symptom/sign during the 19 entire course was sensory disturbance (94.9%), the second most common symptom/sign was 20 motor weakness (92.5%), and the third was gait disturbance (79.5%). Cranial nerves were 21 affected in 75.0%, and optic nerves were the most commonly affected (63.3%) with 22 approximately 50% exhibiting bilateral involvement. Hyporeflexia and hyperreflexia were seen inM A N U S C R I P T disturbance was present in 47.4%. Muscle atrophy and cerebellar ataxia were detected in about 1 25%. Mental disturbance, seizure, and respiratory disturbance were occasionally observed.
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Laboratory findings: Few patients had common autoantibodies and anti-aquaporin 4 (AQP4) 3
antibodies were detected in none of the patients. Cerebrospinal fluid (CSF) protein levels were 4 increased in 82.5% while pleocytosis was present in only 27.5%, indicating albuminocytological 5 dissociation in 57.5%. The CSF oligoclonal IgG bands (OBs) were positive only in 7.4%, and the 6
IgG index was elevated in 18.5%. 7
Magnetic resonance imaging (MRI) and electrophysiological findings: On MRI, cerebral, 8 cerebellar, brainstem, and optic nerve lesions were found in 75.0%, 15.0%, 32.5% and 17.5%, 9
respectively. Extensive lesions (>3 cm in diameter) were observed in 25.0% while gadolinium 10 (Gd)-enhanced lesions were found in only 17.5%. Spinal cord lesions were detected in 75.0%, of 11 which 36.7% were Gd-enhanced. Longitudinally extensive spinal cord lesions (LESCLs), 12 extending three or more vertebral segments, were present in 7.5%. Visual-evoked potentials 13 (VEPs) were abnormal in 71.4%, with bilateral observation of these in 53.3%. In motor nerve 14 conduction studies (NCS), decreased motor nerve conduction velocity (MCV) and prolonged 15 F-wave latency were the most common findings, which were recognized in 77.5% and 70.0%, 16 respectively. Abnormal compound muscle action potential amplitude, prolonged distal latency, 17 and decreased F-wave occurrence were detected in approximately half of the patients. Conduction 18 block and temporal dispersion were detected in 27.5% and 40.0%, respectively. In sensory NCS, 19 decreased or absent sensory nerve action potential was observed in as many as 87.5%, while 20 decreased sensory nerve conduction velocity was present in 42.5%. 21
Treatment response: CCPD patients were most commonly treated with either intravenous or oral 22 corticosteroids, followed by intravenous immunoglobulins, resulting in 83.3%, 75.0%, and 66.7% 23 improvement, respectively. Plasmapheresis was performed in a small fraction of CCPD patients,M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT even exacerbated the disease in 30.0%. At the illness peak, 40.0% of CCPD patients had severe 1 disability (≥ 4 Hughes functional scale score) with some requiring artificial ventilation, whereas 2 after treatment 65.0% had no or only mild disabilities (≤ 1 Hughes functional scale score). We developed a more specific antibody assay using human NF155 and flow cytometry, and found 23 that positivity rates for anti-NF155 antibodies among patients with CIDP, MS, and other 24 neuropathies, and healthy controls were 18% (9/50), 0% (0/32), 2.5% (1/40), and 0% (0/30), Sera from anti-NF155 antibody-positive CIDP patients bind specifically to paranodal regions of 6 peripheral nerves, suggesting the paranodes are primary targets. These sera do not react with 7 neuronal isoform, NF186 (Ogata et al., 2015) , indicating that antigenic epitopes should exist 8 around the extracellular FN3 domain, which is unique to NF155 (Fig. 2) . IgG4 subclass 9
anti-NF155 antibodies predominate in all CIDP patients we have examined (Ogata et al., 2015) . 10
IgG4 has a compact structure because of trans heavy chain CH1-CH2 domain interaction, 11 resulting in no accessibility for complements to the CH2 domain which fix complements. Thus, 12
IgG4 cannot activate complement because it is unable to bind C1q (Huijbers et al., 2015) . Kadoya, M., Kaida, K., Koike, H., Takazaki, H., Ogata, H., Moriguchi, K., Shimizu, J., Nagata, 10 E., Takizawa, S., Chiba, A., Yamasaki, R., Kira, J., Sobue, G., Ikewaki, K., 2016. 
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Autoantibodies against nodal and paranodal proteins, such as neurofascin-186 (NF186), neurofascin-155 (NF155), contactin-1 (CNTN1), contactin-associated protein 1 (CASPR1), and gliomedin, have been discovered in demyelinating diseases, such as multiple sclerosis, chronic inflammatory demyelinating polyradiculoneuropathy, and Guillain-Barré syndrome.
IgG4 subclass autoantibodies against nodal and paranodal proteins are associated with unique features that are collectively termed nodopathy or paranodopathy.
The primary role of IgG4 anti-paranodal protein antibodies may be blockade of interactions between NF155 and CNTN1/CASPR1, leading to conduction failure.
